Avid Urges Stockholders to Vote FOR the Pending Transaction TODAY TUSTIN, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today posted an investor presentation in connection with its pending transaction with GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”) on its investor relations website. Highlights of the presentation include:The transaction with GHO and Ampersand delivers significant, immediate and certain cash value to Avid stockholders:The transaction presents a significant premium to the Company’s share price...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Jan. 08, 2025 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”) is pleased to announce that disinterested shareholders approved the Company’s acquisition of two affiliated home care services companies with operations in Nova Scotia at the special meeting of shareholders held today. The acquisition is a Non-Arm’s Length transaction pursuant to TSX Venture Exchange (“TSXV”) policies. More information on the acquisition is available in the Company’s Management Information Circular dated November 18, 2024 filed on SEDAR+ and the press release dated October 29, 2024. Closing of the acquisition is subject to the satisfaction of certain conditions, including the approval of the TSXV and lender...

A Key Milestone for Therapeutic Exosome Production TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (“NurExone” or the “Company“), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that it has acquired a master cell bank from a U.S. manufacturer for an undisclosed amount (the “Acquisition”). The Acquisition marks a major step in ensuring a stable and scalable supply chain for production of exosome-based therapies for clinical needs and eventual patient treatment. The master cell bank provides a well-characterized, Good Manufacturing Practices (“GMP”) grade and exclusive source of human bone marrow mesenchymal stem cells (“MSCs”), the foundation for producing exosomes. The acquired master cell...

NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) — FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFERRules 8.1 and 8.2 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: HOOKIPA Pharma Inc.(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree HOOKIPA Pharma Inc. (Offeror)(d)   Is the discloser the offeror or the offeree? Offeror(e)   Date position held:        The latest practicable date prior to the disclosure 7 January 2025(f)   In...

AMENDED DISCLOSURE – PLEASE REFER TO SECTIONS 2(a) AND 3(a) 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Learning Technologies Group Plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date...

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Kolter Capital NWH LLC (Kolter Capital), an affiliate of the Kolter Group LLC (Kolter Group) announced today that it has acquired an additional 100,000 units (Units) of Northwest Healthcare Properties Real Estate Investment Trust (the REIT) in the open market through the facilities of the Toronto Stock Exchange at an average price of CAD$4.6169 per Unit, for an aggregate purchase price of CAD$461,690 (the Acquisition). Immediately prior to completion of the Acquisition, Kolter Capital beneficially owned or exercised control or direction over 24,663,400 Units, representing approximately 9.99% of the issued and outstanding Units. Upon completion of the Acquisition, Kolter Capital now beneficially owns or exercises control or direction over 24,763,400 Units, representing approximately 10.03%...

Bateau Asset Management brings to SMC Entertainment:Foundational acquisition into International Financial Services Sector Well-established client base of high-net-worth individuals Experienced global client services team based in Australia and Singapore Research and advisory capabilities complementary to SMC Entertainment’s Fintech platformBOCA RATON, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) — SMC Entertainment, Inc. (“SMC” or the “Company”) (OTC PINK: SMCE), a Fintech incubator company focused on acquisition and support of commercialized financial services and technology (Fintech) companies, is pleased to announce that it has closed the Acquisition Agreement to acquire a 100% interest in Australia-based Bateau Asset Management, a boutique investment manager (“Bateau”). The acquisition will provide SMC with...

All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder Value WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development pipeline. The Company will seek acquisition targets to achieve the Company’s new corporate strategy. Windtree believes there is an opportunity in the market: the acquisition of small companies with FDA-approved...

Downing LLPLEI: 213800G3X76VBG9SB50408 January 2025Form 8.3 re. Team Internet Group Plc PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Downing LLP(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):Client funds managed by Downing LLP(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:Team Internet Group Plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: n/a(e)   Date position held/dealing undertaken:07 January 2025(f)   In addition to the company in 1(c) above, is the discloser making disclosures...

On January 7, 2025, Hydro finalized the open market repurchase of the 2024-2025 buyback program as announced on September 10, 2024. The total program comprises 30 526 862 shares, of which 20 067 969 shares were repurchased in the market. The remaining 10 458 893 shares will be purchased from the Norwegian state through the Ministry of Trade, Industry and Fisheries, and therefore the Ministry’s ownership interest in Norsk Hydro ASA of 34.26% will remain unchanged. The 30 526 862 shares will be cancelled following approval by the Annual General Meeting in May 2025. The shares that have been repurchased in the open market have had an immediate cash effect, whereas the pro rata shares from the Norwegian state will be paid simultaneously with the capital reduction in mid-2025. The weighted average price for the 20 067 969 shares was NOK...